Serum IL-5 and IFN-γ Are Novel Predictive Biomarkers for Anti-PD-1 Treatment in NSCLC and GC Patients

Table 1

The clinicopathological parameters of patients.

Parameters	NSCLC	Gastric cancer
Gender, (%)
Male	34 (85)	23 (65.7)
Female	6 (15)	12 (34.3)
Age (year)
⩽60	13 (32.5)	10 (28.5)
>60	27 (67.5)	25 (71.5)
Has smoking history	32 (80)	21 (60)
Brain metastasis	2	0
Eastern Cooperative Oncology Group status (ECOG), (%)
0	7 (17.5)	2 (5.7)
1	30 (75)	26 (74.2)
2	3 (7.5)	7 (20.1)
Adenocarcinoma	26 (65)	35 (100)
Squamous cell carcinoma	14 (35)	0
First-line treatment	18 (45)	9 (25.7)
Second- and third-line treatment	22 (55)	26 (74.2)
Complete remission (CR)	4 (10)	2 (5.7)
Partial remission (PR)	12 (30)	6 (17.1)
Stable disease (SD)	13(32.5)	9 (25.7)
Disease progression (PD)	9 (22.5)	18 (51.4)